N,N-dimethyltryptamine (DMT) is a psychedelic compound, believed to have potential as a therapeutic option in depression and several other psychiatric disorders.
Read about the relationship between drug exposure of DMT and the intensity of psychedelic experience, as well as on its effect on the EEG spectrum, in two new publications by a Pharmetheus colleague and academic collaborators.
“Here”, comments Daniel Röshammar, we explore how DMT affects the brain in healthy subjects and what doses are eliciting psychedelic effects. An understanding that might prove important in increasing the chances for choosing appropriate dose levels and endpoints in the future clinical development of DMT in various patient populations.”
The results indicate that increasing the dose above 14 mg might not provide any substantial increase in psychedelic experience, as 92% of the population is predicted to already achieve an intensity score above five on the 10 graded scale. To keep patients at sub-psychedelic levels, doses higher than 7 mg should be avoided. The results also indicate that there is a quantitative relationship between DMT concentrations and the observed effects on the EEG spectrum. The most robust relationship appears to be that between DMT and suppression in alpha power.
Find the publications here:
1. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine – Implications for dose considerations.
2. N,N-dimethyltryptamine affects EEG response in a concentration dependent manner – a pharmacokinetic/pharmacodynamic analysis.
Pharmetheus affiliate: Daniel Röshammar